Cancer is "an evolutionary disease," writes Carl Zimmer at the New York Times. Treat it with one drug, see an improvement, but then it finds a way around the treatment to recur. Johns Hopkins University's Bert Vogelstein, he adds, is using mathematics to model such resistances and recurrence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.